Margaret Hills
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Journal: Breast cancer research : BCR
Published: December 02, 2022
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Journal: Breast cancer research : BCR
Published: February 18, 2022
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Journal: EBioMedicine
Published: February 18, 2022
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).
Journal: Therapeutic advances in medical oncology
Published: May 14, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Journal: Cancer discovery
Published: April 30, 2020
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Journal: Breast cancer research : BCR
Published: February 02, 2020
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Journal: Breast cancer research : BCR
Published: July 02, 2019
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 20, 2017
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Journal: Breast cancer research and treatment
Published: April 18, 2017
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Journal: Nature communications
Published: October 13, 2016
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
Journal: Breast cancer research : BCR
Published: October 19, 2015
Last Updated: 09/26/2026